A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

Juvenile Idiopathic Arthritis Clinical Trial

Official title:

A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01734382
• Other study ID #: WA28029
• Secondary ID: 2012-000444-10
• Status: Completed
• Phase: Phase 4
• Start date: June 10, 2013
• Est. completion date: October 9, 2019

Study information

• Verified date: April 2020
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks. Participants who experience a laboratory abnormality during Part 1 may be eligible to move into Part 2 of the study.

PART 2 This open-label Phase IV study will evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of tocilizumab in reduced dose frequency in participants with adequately controlled systemic juvenile idiopathic arthritis who have experienced a laboratory abnormality on twice weekly tocilizumab dosing, that has since resolved. Participants will receive tocilizumab 12 mg/kg or 8 mg/kg intravenously every 3 weeks. After 5 consecutive infusions, participants who experience an event of neutropenia, thrombocytopenia or liver enzyme abnormality will move to every 4 weeks tocilizumab administration. Anticipated time on study treatment is 52 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: October 9, 2019
• Est. primary completion date: October 9, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 17 Years

Eligibility

Inclusion Criteria:

PART 1 and 2

• Children 2 to 17 years of age inclusive at screening

• Systemic juvenile idiopathic arthritis (sJIA) according to International League of Associations for Rheumatology (ILAR) classification (2001) and sJIA symptoms lasting for at least 1 month since diagnosis of sJIA

• Must meet one of the following:

• Not receiving methotrexate (MTX) or discontinued MTX at least 4 weeks prior to baseline visit, or

• Taking MTX for at least 12 weeks immediately prior to the baseline visit and on a stable dose of less than or equals (</=) 20 milligrams per meter square (mg/m^2) for at least 8 weeks prior to the baseline visit, together with either folic acid or folinic acid according to local standard of care

• Participants entering Part 1 who are naive to TCZ therapy must also meet the following inclusion criterion:

• History of inadequate clinical response (in the opinion of the treating physician) to Non steroidal Anti-Inflammatory Drugs (NSAIDs) and corticosteroids PART 2

• Juvenile Arthritis Disease Activity Score (JADAS) -71 score of 3.8 or less and absence of fever (related to sJIA) at screening and baseline

• Neutropenia, thrombocytopenia, or elevated Alanine transaminase/Aspartate transaminase (ALT/AST) previously experienced on the labeled dose (Q2W) of RoActemra/Actemra at any time

• Not currently receiving oral corticosteroids, or taking oral corticosteroids at a stable dose for a minimum of 2 weeks prior to baseline visit at no more than 10 milligrams per day (mg/day) or 0.2 miiligrams per kilogram per day (mg/kg/day), whichever is less

• Not taking (NSAIDs), or taking no more than 1 type of NSAID at a stable dose for a minimum of 2 weeks prior to the baseline visit, with the dose being less than or equal to the maximum recommended daily dose

Exclusion Criteria:

• Wheelchair bound or bedridden

• Any other auto-immune, rheumatic disease, or overlap syndrome other than sJIA

• Pregnant or lactating, or intending to become pregnant during study conduct and up to 6 months after the last administration of study drug

• Any significant concurrent medical or surgical condition which would jeopardize the participant's safety or ability to complete the trial

• History of significant allergic or infusion reactions to prior TCZ infusion, and/or presence of anti-TCZ antibodies at screening

• Inborn conditions characterized by a compromised immune system

• Known Human Immunodeficiency Virus (HIV) infection or other acquired forms of immune compromise

• History of alcohol, drug, or chemical abuse within 6 months of screening

• Evidence of serious uncontrolled concomitant diseases, including but not limited to the nervous, renal, hepatic, or endocrine systems

• Any active acute, subacute, chronic or recurrent bacterial, viral, or systemic fungal infection

• History of atypical tuberculosis (TB)

• Active TB requiring treatment within 2 years prior to the screening visit

• Positive purified protein derivative (PPD) at screening

• Any major episode of infection requiring hospitalization or treatment during screening or treatment with IV antibiotics completing within 4 weeks of the screening visit or oral antibiotics completing within 2 weeks of the screening visit

• History of reactivation or new onset of a systemic infection within 2 months of the screening visit

• Positive for hepatitis B or hepatitis C infection

• Chronic hepatitis, viral or pulmonary disease

• Significant cardiac or pulmonary disease

• History of or current cancer or lymphoma

• Uncontrolled diabetes mellitus

• History of or concurrent serious gastrointestinal disorders

• History of macrophage activation syndrome (MAS) within 3 months prior to screening visit

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Juvenile
• Juvenile Idiopathic Arthritis

Intervention

Drug:
• Tocilizumab
Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants < 30 kg) or 8 mg/kg (for participants >/=30 kg) Q2W/Q3W/Q4W.

Locations

Country	Name	City	State
Argentina	Hospital Gral de Niños Pedro Elizalde	Buenos Aires
Argentina	Hospital Dr. Humberto Notti	Mendoza
Canada	Alberta Children'S Hospital	Calgary	Alberta
Germany	Charité Campus; Virchow Klinikum Berlin	Berlin
Germany	Asklepios Klinik; Zentrum für Allgemeine Pädiatrie und Neonatologie	Sankt Augustin
Israel	Rambam Medicl Center, Ruth Children Hospital	Haifa
Israel	Meir Medical center, Pediatrics	Kfar Sava
Israel	Schneider Children's Medical Center of Israel	Petach Tikva
Italy	Univ. Di Padova - Dip. Di Pediatria - Unita' Reumatol. Pediatrica	Padova	Veneto
Italy	Irccs Ospedale Pediatrico Bambin Gesu - Dip. Di Medicina	Roma	Lazio
Mexico	Unidad de Reumatologia Rehabilitacion Integral; Centro Medico Del Angel	Mexicali
Russian Federation	SI Sceintific children health center RAMS	Moscow
Russian Federation	Saint-Petersburg State; Pediatrics Medical Academy	Saint-Petersburg
Spain	Hospital Sant Joan De Deu; Servicio de Reumatologia Pediatrica	Barcelona
Spain	Hospital de La Paz; Unidad de Reumatologia Pediatrica	Madrid
Spain	Hospital Ramon y Cajal ; Servicio de Reumatologia	Madrid
United Kingdom	Royal Liverpool Childrens Hospital; Rheumatology	Liverpool
United States	Cincinnati Children'S Hospital Medical Center; Division of Rheumatology	Cincinnati	Ohio
United States	Children's Hospital Los Angeles; Division of Rheumatoogy	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

United States,  Argentina,  Canada,  Germany,  Israel,  Italy,  Mexico,  Russian Federation,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Juvenile Arthritis Disease Activity Score (JADAS-71)	JADAS-71 has 4 components: Physician global assessment of disease activity on a visual analog scale (VAS) (range=0-10, left end of line=arthritis inactive, i.e., symptom-free and no arthritis symptoms; right end=arthritis very active), patient/parent global assessment of overall well-being on VAS (range=0-10, left end of line=very well, right end=very poor), normalized erythrocyte sedimentation rate (ESR) (range=0-10, If ESR is =20 mm/h, set to 0. If =120 mm/h, set to 10 mm/h. If > 20 mm/h and < 120 mm/h, apply formula: [ESR-20 mm/h]/10 mm/h), and a count of active arthritis (swelling present or pain present and limitation of motion) in 71 selected joints (range=0-71). JADAS-71 is sum of 4 component scores, range=0-101. A higher score=more arthritis disease activity. Data reported for up to Week 52 was collected in Part 2: Q3W arms: Baseline, Weeks 3,6,9,12,24,36,48 and 51; Q4W arms: Baseline, Weeks 0,4,8,12,24,36 and 40.	Part 2: Up to 52 weeks
Primary	Number of Participants With Juvenile Idiopathic Arthritis (JIA) Disease Flare as Determined by JIA Core Variables in Part 2 of the Study	JIA flare was defined as any 3 of the 6 core outcome variables worsening by at least 30% relative to baseline visit of Part 2, with no more than 1 of the remaining variables improving by more than 30%. For the number of joints with active arthritis or the number of joints with limitation of motion a minimum worsening of at least 2 joints had to be present. If the physician global assessment (PGA) or the parent/patient global assessment were used a minimum worsening of at least 2 units on a scale from 0 to 10 had be present. For erythrocyte sedimentation rate (ESR), a worsening of at least 30% was not considered if within normal ranges. The 6 core outcome variables: PGA of disease activity, parent/patient global assessment of overall well-being, number of joints with active arthritis, number of joints with limitation of movement, ESR (measure of acute phase reaction) and functional ability determined by Childhood Health Assessment Questionnaire (CHAQ) Disability Index.	Part 2: Up to 52 weeks
Primary	Number of Participants With Fever Attributable to Systemic Juvenile Idiopathic Arthritis (sJIA) in Part 2 of the Study	Absence of fever at screening visit was defined as a temperature measurement < 38 degree centigrades (C). Presence of fever at each study visit was defined as a temperature measurement = 38 C.	Part 2: Up to 52 weeks
Secondary	Number of Participants With at Least One Adverse Event	An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.	Part 1 - Baseline up to 24 weeks plus 12 weeks of safety follow up; Part 2 - Baseline up to 52 weeks plus 12 weeks of safety follow up
Secondary	Serum Interleukin-6 (IL-6) Protein Concentration in Part 2 of the Study		Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Secondary	Soluble IL-6 Receptor (sIL-6R) Protein Concentration in Part 2 of the Study		Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Secondary	C-reactive Protein (CRP) Concentration in Part 2 of the Study		Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Secondary	Erythrocyte Sedimentation Rate (ESR) in Part 2 of the Study		Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Secondary	Number of Participants With Anti-TCZ Antibodies in Part 2 of the Study		Part 2: Up to Week 52
Secondary	Serum TCZ Concentration in Part 2 of the Study		Part 2: Q3W arms: Pre-dose at Baseline, Weeks 3, 6, 9, 12, 24, 36, 48 and 51; Q4W arms: Pre-dose at Baseline, Weeks 0, 4, 8, 12, 24, 36 and 40
Secondary	Baseline Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2 of the Study	CHAQ- Disability Index consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on 4-point scale with range 0=no difficulty to 3=unable to do. To calculate overall score, participant must have a domain score in at least 6 of 8 domains. Scores were averaged to calculate CHAQ disability index, range is 0=no/minimal physical dysfunction)-3=very severe physical dysfunction, higher score indicates more disability.	Baseline of Part 2
Secondary	Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index in Part 2 of the Study	CHAQ- Disability Index consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on 4-point scale with range 0=no difficulty to 3=unable to do. To calculate overall score, participant must have a domain score in at least 6 of 8 domains. Scores were averaged to calculate CHAQ disability index, range is 0=no/minimal physical dysfunction)-3=very severe physical dysfunction, higher score indicates more disability. Negative change from baseline indicates an improvement.	Baseline; Part 2: Q3W arm groups - Weeks 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48 and 51; Q4W arm groups - Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 40
Secondary	Baseline Participant's/Parent's Global Assessment of Overall Well-being Score in Part 2 of the Study	Participant's/parent's global assessment of overall well-being was determined on a VAS (range = 0-100, left end of the line = very well, i.e., symptom-free and no arthritis disease activity; right end = very poor, i.e., maximum arthritis disease activity).	Baseline of Part 2
Secondary	Change From Baseline in Participant's/Parent's Global Assessment of Overall Well-being Score in Part 2 of the Study	Participant's/Parent's global assessment of overall well-being was determined on a VAS (range = 0-100, left end of the line = very well, i.e., symptom-free and no arthritis disease activity; right end = very poor, i.e., maximum arthritis disease activity). Reported is the change from baseline in VAS score with a negative change from baseline indicating an improvement.	Baseline; Part 2: Q3W arm groups - Weeks 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48 and 51; Q4W arm groups - Weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36 and 40